
|Articles|August 19, 2019
ASRS 2019 Street Team: Raj K. Maturi, MD
Author(s)Julianne Mobilian
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process
Advertisement
Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Navigating the Gray Zone in MacTel Type 2: When to Treat Early or Advanced Disease
2
Real-World Insights From Diagnosis to Treatment in Macular Telangiectasia Type 2 Care
3
Selecting the Treatment Eye and Overcoming Implementation Barriers in MacTel Type 2 Management
4
Managing Bilateral MacTel Type 2: Prioritizing Eye Selection and Patient Counseling for NT-501 Implantation Therapy
5

















































